Medical Devices · us
New Option for Leaks Around Prosthetic Heart Valves as FDA Approves Abbott Catheter-Based Closure Device
After valve replacement surgery, gaps between a prosthetic valve and heart tissue can allow blood to flow backward, potentially causing heart failure symptoms or hemolysis. Abbott’s newly approved closure device offers some patients in the United States an alternative to repeat open-heart surgery, but its scope of use and long-term outcomes remain limited.
After heart valve replacement, patients sometimes face another challenge: gaps that remain or gradually form around the prosthetic valve, allowing blood to flow backward around it. Treating this type of “paravalvular leak” may require repeat open-heart surgery. Abbott announced on October 28 that its Amplatzer Paraclose PVL Occluder had received approval from the U.S. Food and Drug Administration (FDA), adding a transcatheter closure treatment option for eligible patients.
Paravalvular leaks occur at the seal between a prosthetic valve and native heart tissue. According to Abbott, leakage may be accompanied by heart failure symptoms such as shortness of breath, fatigue and swelling in the lower limbs. It may also damage red blood cells, causing hemolytic anemia. Treatment must therefore close the gap while preserving the prosthetic valve’s existing function.
The device is delivered through a catheter inserted into an artery or vein in the leg and positioned at the leak opening. Its design accommodates elongated oval and crescent-shaped gaps and is suitable for mechanical or biological valves. According to the product labeling, the approved indication is limited to clinically significant paravalvular leaks associated with surgically implanted aortic or mitral prosthetic valves. It cannot be broadly applied as a universal treatment for all leaks following valve replacement.
Approval was supported by the PARADIGM study, a prospective, multicenter, single-arm study that enrolled 200 patients. Abbott said the findings supported the device’s safety and effectiveness; however, the announcement did not provide specific closure success rates, major adverse event rates or follow-up results. Without a randomized control group, this study alone also cannot establish how much the device reduces risk compared with repeat surgery or whether it offers a survival advantage.
The size of a patient’s gap and the stability of the valve are important limits on use. Contraindications listed for the product include active endocarditis, rocking of the prosthetic valve, leakage extending over more than half the valve’s circumference, and a defect with a short axis greater than 5 millimeters. In other words, even if a catheter can reach the gap, closure with this device may not be appropriate.
Transcatheter treatment itself still carries risks. The product’s safety information lists potential adverse events including device embolization, interference with valve function, stroke, and residual or recurrent regurgitation. These are listed risks, not published incidence rates from the PARADIGM study. Whether closure can remain stable while avoiding interference with valve function remains central to assessing treatment outcomes.
Cardiovascular Business reported the same day that this is the first transcatheter device in the United States to receive FDA approval specifically for treating paravalvular leaks. The same product has been available in Europe since 2020 under the name Amplatzer Valvular Plug III. This development gives U.S. patients an additional option with a specific indication, while complete study data and longer-term follow-up will help clarify which patients are most likely to experience sustained benefit.